CRO CNR Research announced that it has signed a contract for global clinical trial collaboration with Advanced Clinical, a global CRO company headquartered in Chicago, USA. The main content of this contract is to conduct a global phase 2 clinical trial project in Korea.
This study is an early-stage global clinical trial targeting patients with Non-Cystic Fibrosis Bronchiectasis, a rare disease. The study will be conducted at seven major medical institutions in Korea, and CNR Research will take the lead in conducting the clinical trial.
Advanced Clinical is a global CRO company that provides integrated clinical services in the US, Europe, and Asia-Pacific regions, and has secured trust in the industry with a 77% contract renewal rate and a customer satisfaction score of 4.7 or higher for 27 consecutive quarters.
This project is being conducted at the request of Australian biopharmaceutical company CSL. CSL is a global pharmaceutical company developing various new drugs in the fields of rare diseases, gene therapy, and vaccines, and directly selected CNR Research as the local project implementation partner.
CNR Research explained that Vice President Hyun Mi-sook (CPO Headquarters Director) played a major role in the process of concluding this partnership. Vice President Hyun contributed to negotiations and contract conclusion based on her experience at domestic and international pharmaceutical companies and the global CRO Quintiles Korea (now IQVIA KOREA).
Starting with this agreement, the two companies are also exploring the possibility of additional cooperation in the Asian region. During the upcoming '2025 Bio Korea' event, the general manager of Advanced Clinical's Japanese subsidiary is scheduled to visit Korea to discuss ways to expand cooperation with CNR Research.
“International partnerships are essential to grow into a global CRO,” said a CNR Research official. “This project will be an important opportunity to strengthen CNR Research’s global clinical capabilities.”
- See more related articles
You must be logged in to post a comment.